Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

BACKGROUND: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). METHODS: Multicenter, observational study, in which, information of 388 patients randomly selected and treate...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur Neurol
Auteurs principaux: Meca-Lallana, José, Ayuso, Teresa, Martínez-Yelamos, Sergio, Durán, Carmen, Contreras Martín, Yessica, Herrera Navarro, Nicolás, Pérez Sempere, Angel, Álvarez-Cermeño, Jose C., Millán Pascual, Jorge, Meca-Lallana, Virginia, Romero Sevilla, Raúl, Ricart, Javier
Format: Artigo
Langue:Inglês
Publié: S. Karger AG 2020
Sujets:
Clinical Neurology: Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265769/
https://ncbi.nlm.nih.gov/pubmed/32187609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000505778
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires